Treatment of comorbid tuberculosis and depression

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 3, Issue 6, 2001, Pages 236-243

  Trenton, Adam J ^a,b   Currier, Glenn W ^a  

^a School of Medicine   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646489364     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/PCC.v03n0610     Document Type: Article

References (46)

1. Poponick JM, Moll J. Tuberculosis. In: Tintinalli JE, Kelen GD, Stapczynski JS, eds. Emergency Medicine. New York, NY: McGraw-Hill; 2000:466-471
2. Iseman MD. Tuberculosis. In: Goldman LG, Bennett JC, eds. Cecil Textbook of Medicine. Philadelphia, Pa: WB Saunders Co; 2000:1723-1731
3. McQuistion HL, Colson P, Yankowitz R, et al. Tuberculosis infection among people with severe mental illness. Psychiatr Serv 1997;48:833-835
4. Westaway MS, Wolmarans L. Depression and self-esteem: rapid screening for depression in black, low literacy, hospitalized tuberculosis patients. Soc Sci Med 1992;35:1311-1315
5. Moffic HS, Paykel ES. Depression in medical in-patients. Br J Psychiatry 1975; 126:346-353
6. Cavanaugh SV. The prevalence of emotional and cognitive dysfunction in a general medical population: using the MMSE, GHQ, and BDI. Gen Hosp Psychiatry 1983;5:15-24
7. Lopez AG. Tuberculosis and the severely mentally ill [letter]. Am J Psychiatry 1994;151:151-152
8. Fullilove MT, Young R, Panzer PG, et al. Psychosocial issues in the management of patients with tuberculosis. J Law Med Ethics 1993;21:1324-331
9. Saez H, Valencia E, Conover S, et al. Tuberculosis and HIV among mentally ill men in a New York City shelter. Am J Pub Health 1996;86:1318-1319
10. Sanchez M, Nicholls T, Currier G. Risk factors for tuberculosis in the psychiatric emergency department. Emerg Psychiatry 1998;4:33-34
11. Chesnutt MS, Prendergast TJ. Lung. In: Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment. New York, NY: Lange Medical Books/McGraw-Hill; 2000:301-307
12. Friedman LN. Skin testing and chemoprophylaxis. In: Friedman LN, ed. Tuberculosis: Current Concepts and Treatment. 2nd ed. New York, NY: CRC Press; 2001:377-411
13. Curtis AM. Radiology of mycobacterial disease. In: Friedman LN, ed. Tuberculosis: Current Concepts and Treatment. 2nd ed. New York, NY: CRC Press; 2001:271-300
14. Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999;58:633-661
15. Chambers HF. Mycobacterium tuberculosis infections. In: Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment. New York, NY: Lange Medical Books/McGraw-Hill; 2000:1384-1386
16. Jacobs RA, Guglielmo J. Anti-infective chemotherapeutic and antibiotic agents. In: Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment. New York. NY: Lange Medical Books/ McGraw-Hill; 2000:1518-1521
17. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:623-625
18. Stricof RL, DiFerdinando GT Jr, Osten WM, et al. Tuberculosis control in New York City hospitals. Am J Infect Control 1998;26:270-276
19. Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-911
20. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-532
21. Fischl MA, Daikos GL, Uttamchandani RB, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992;117:184-190
22. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1997;32(suppl 1):1-21
23. Robinson DS, Lovenberg W, Keiser H, et al. Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol 1968;17:109-119
24. Evans ME, Kortas KJ. Potential interaction between isoniazid and selective serotonin reuptake inhibitors. Am J Health Syst Pharm 1995;52: 2135-2136
25. Malek-Ahmadi P, Chavez M, Contreras SA. Coadministration of isoniazid and antidepressant drugs [letter]. J Clin Psychiatry 1996;57:550
26. Judd FK, Mijch AM, Cockram A, et al. Isoniazid and antidepressants: is there cause for concern? Int Clin Psychopharmacol 1994;9:123-125
27. Smith CK, Durack DT. Isoniazid and reaction to cheese. Ann Intern Med 1978;88:520-521
28. Stockley IH. Lack of clinical evidence for potential interaction between isoniazid and selective serotonin-reuptake inhibitors [letter]. Am J Health Syst Pharm 1996;53:2217
29. Tseng A. AIDS/HIV: drugs for opportunistic infections. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. Totowa, NJ: Humana Press; 2001:61-107
30. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001;45:382-392
31. Sindrup SH, Brosen K, Hansen MGJ, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-17
32. Baumann P, Nil R, Souche A, et al. A double-blind placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharamacokinetic, and pharmacogenic investigation. J Clin Psychopharmacol 1996;16:307-314
33. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-desmethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280:927-933
34. Gram LF, Hansen MGJ, Sindrup SH, et al. Citalopram: interaction studies with levopromazine, imipramine, and lithium. Ther Drug Monit 1993;15: 18-24
35. Caccia S. Metabolism of the newer antidepressants. Clin Pharmacokinet 1998;34:281-302
36. Rudorfer MV. Monoamine oxidase inhibitors: reversible and irreversible. Psychopharmacol Bull 1992;28:45-57
37. Jacobsen E. The early history of psychotherapeutic drugs. Psychopharmacology (Berl) 1986;89:138-144
38. Zeller EA, Barsky J, Fouts JR, et al. Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 1952;8:349-350
39. Crane GE. Further studies on iproniazid phosphate. J Nerv Ment Dis 1956; 124:322-331
40. Goff DC, Tsai G, Levitt J, et al. A placebo controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56:21-27
41. van Berckel BNM, Hijman R, van der Linden JA. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996;40:1298-1300
42. Cascella NG, Macciardi F, Cavallini C, et al. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm 1993;95:105-111
43. Goff DC, Tsai G, Manoach DS, et al. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995;152:1213-1215
44. Pasargiklian M, Biondi L. Neurologic and behavioural reactions of tuberculous patients treated with cycloserine. Scand J Respir Dis Suppl 1970; 71:201-208
45. Goff DC, Henderson DC, Evins AE, et al. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999;45:512-514
46. Goff DC, Tsai G, Manoach DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996;153:1628-1630